Datasets:

nzindoc

/

dataset-multiple-myeloma

like 0

The correlation between the median PFS for G-CSF Plus Plerixafor and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for G-CSF Plus Plerixafor and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

The impact of side effects and adverse reactions on the median PFS for G-CSF Plus Plerixafor.

The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for G-CSF Plus Plerixafor. ### Response: The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

The role of supportive care in improving the median PFS for G-CSF Plus Plerixafor.

The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for G-CSF Plus Plerixafor. ### Response: The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for G-CSF Plus Plerixafor.

The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for G-CSF Plus Plerixafor. ### Response: The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

The effect of concurrent health conditions on the median PFS for G-CSF Plus Plerixafor.

The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for G-CSF Plus Plerixafor. ### Response: The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Median PFS for G-CSF Plus Placebo?

The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for G-CSF Plus Placebo? ### Response: The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Comparison of the median PFS for G-CSF Plus Placebo with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for G-CSF Plus Placebo with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

The impact of patient characteristics on the median PFS for G-CSF Plus Placebo.

The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for G-CSF Plus Placebo. ### Response: The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

The role of genetic factors in the median PFS for G-CSF Plus Placebo.

The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for G-CSF Plus Placebo. ### Response: The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

The influence of previous treatments on the median PFS for G-CSF Plus Placebo.

The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for G-CSF Plus Placebo. ### Response: The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

The effect of dosage and administration frequency on the median PFS for G-CSF Plus Placebo.

The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for G-CSF Plus Placebo. ### Response: The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

The correlation between the median PFS for G-CSF Plus Placebo and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for G-CSF Plus Placebo and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

The impact of side effects and adverse reactions on the median PFS for G-CSF Plus Placebo.

The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for G-CSF Plus Placebo. ### Response: The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

The role of supportive care in improving the median PFS for G-CSF Plus Placebo.

The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for G-CSF Plus Placebo. ### Response: The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for G-CSF Plus Placebo.

The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for G-CSF Plus Placebo. ### Response: The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

The effect of concurrent health conditions on the median PFS for G-CSF Plus Placebo.

The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for G-CSF Plus Placebo. ### Response: The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Placebo from AMD3100-3102 was 34 months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)}

Median PFS for Melphalan, Autologous PBSCT, Lenalidomide?

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Melphalan, Autologous PBSCT, Lenalidomide? ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Comparison of the median PFS for Melphalan, Autologous PBSCT, Lenalidomide with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Melphalan, Autologous PBSCT, Lenalidomide with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The impact of patient characteristics on the median PFS for Melphalan, Autologous PBSCT, Lenalidomide.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Melphalan, Autologous PBSCT, Lenalidomide. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The role of genetic factors in the median PFS for Melphalan, Autologous PBSCT, Lenalidomide.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Melphalan, Autologous PBSCT, Lenalidomide. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The influence of previous treatments on the median PFS for Melphalan, Autologous PBSCT, Lenalidomide.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Melphalan, Autologous PBSCT, Lenalidomide. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The effect of dosage and administration frequency on the median PFS for Melphalan, Autologous PBSCT, Lenalidomide.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Melphalan, Autologous PBSCT, Lenalidomide. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The correlation between the median PFS for Melphalan, Autologous PBSCT, Lenalidomide and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Melphalan, Autologous PBSCT, Lenalidomide and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Melphalan, Autologous PBSCT, Lenalidomide.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Melphalan, Autologous PBSCT, Lenalidomide. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The role of supportive care in improving the median PFS for Melphalan, Autologous PBSCT, Lenalidomide.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Melphalan, Autologous PBSCT, Lenalidomide. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Melphalan, Autologous PBSCT, Lenalidomide.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Melphalan, Autologous PBSCT, Lenalidomide. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The effect of concurrent health conditions on the median PFS for Melphalan, Autologous PBSCT, Lenalidomide.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Melphalan, Autologous PBSCT, Lenalidomide. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Lenalidomide from CALGB was 57.3 months with a 95% Confidence Interval (CI) of (144.2, 73.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Median PFS for Melphalan, Autologous PBSCT, Placebo?

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Melphalan, Autologous PBSCT, Placebo? ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Comparison of the median PFS for Melphalan, Autologous PBSCT, Placebo with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Melphalan, Autologous PBSCT, Placebo with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The impact of patient characteristics on the median PFS for Melphalan, Autologous PBSCT, Placebo.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Melphalan, Autologous PBSCT, Placebo. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The role of genetic factors in the median PFS for Melphalan, Autologous PBSCT, Placebo.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Melphalan, Autologous PBSCT, Placebo. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The influence of previous treatments on the median PFS for Melphalan, Autologous PBSCT, Placebo.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Melphalan, Autologous PBSCT, Placebo. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The effect of dosage and administration frequency on the median PFS for Melphalan, Autologous PBSCT, Placebo.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Melphalan, Autologous PBSCT, Placebo. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The correlation between the median PFS for Melphalan, Autologous PBSCT, Placebo and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Melphalan, Autologous PBSCT, Placebo and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Melphalan, Autologous PBSCT, Placebo.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Melphalan, Autologous PBSCT, Placebo. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The role of supportive care in improving the median PFS for Melphalan, Autologous PBSCT, Placebo.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Melphalan, Autologous PBSCT, Placebo. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Melphalan, Autologous PBSCT, Placebo.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Melphalan, Autologous PBSCT, Placebo. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

The effect of concurrent health conditions on the median PFS for Melphalan, Autologous PBSCT, Placebo.

The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Melphalan, Autologous PBSCT, Placebo. ### Response: The median progression-free survival (PFS) for the treatment combination of Melphalan, Autologous PBSCT, Placebo from CALGB was 28.9 months with a 95% Confidence Interval (CI) of (22.0, 36.3) ^{[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30140-0/fulltext)}

Median PFS for Bortezomib+Dexamethasone (Vd)?

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Bortezomib+Dexamethasone (Vd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Comparison of the median PFS for Bortezomib+Dexamethasone (Vd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Bortezomib+Dexamethasone (Vd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The impact of patient characteristics on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The role of genetic factors in the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The influence of previous treatments on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The effect of dosage and administration frequency on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The correlation between the median PFS for Bortezomib+Dexamethasone (Vd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Bortezomib+Dexamethasone (Vd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The role of supportive care in improving the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The effect of concurrent health conditions on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from CASTOR was 7.1 months with a 95% Confidence Interval (CI) of (6.2, 7.9) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Median PFS for Daratumumab?

The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Daratumumab? ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Comparison of the median PFS for Daratumumab with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Daratumumab with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The impact of patient characteristics on the median PFS for Daratumumab.

The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Daratumumab. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The role of genetic factors in the median PFS for Daratumumab.

The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Daratumumab. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The influence of previous treatments on the median PFS for Daratumumab.

The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Daratumumab. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The effect of dosage and administration frequency on the median PFS for Daratumumab.

The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Daratumumab. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The correlation between the median PFS for Daratumumab and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Daratumumab and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Daratumumab.

The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Daratumumab. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The role of supportive care in improving the median PFS for Daratumumab.

The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Daratumumab. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Daratumumab.

The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Daratumumab. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The effect of concurrent health conditions on the median PFS for Daratumumab.

The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Daratumumab. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab from CASSIOPEIA was Not Reached months with a 95% Confidence Interval (CI) of (NE, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Median PFS for Observation Only?

The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Observation Only? ### Response: The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Comparison of the median PFS for Observation Only with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Observation Only with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The impact of patient characteristics on the median PFS for Observation Only.

The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Observation Only. ### Response: The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The role of genetic factors in the median PFS for Observation Only.

The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Observation Only. ### Response: The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The influence of previous treatments on the median PFS for Observation Only.

The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Observation Only. ### Response: The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The effect of dosage and administration frequency on the median PFS for Observation Only.

The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Observation Only. ### Response: The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The correlation between the median PFS for Observation Only and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Observation Only and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Observation Only.

The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Observation Only. ### Response: The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The role of supportive care in improving the median PFS for Observation Only.

The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Observation Only. ### Response: The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Observation Only.

The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Observation Only. ### Response: The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The effect of concurrent health conditions on the median PFS for Observation Only.

The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Observation Only. ### Response: The median progression-free survival (PFS) for the treatment combination of Observation Only from CASSIOPEIA was 46.7 months with a 95% Confidence Interval (CI) of (40, NE) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd)?

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Comparison of the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The impact of patient characteristics on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The role of genetic factors in the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The influence of previous treatments on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The effect of dosage and administration frequency on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The correlation between the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The impact of side effects and adverse reactions on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The role of supportive care in improving the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The influence of disease stage at the start of treatment on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The effect of concurrent health conditions on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd)?

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Comparison of the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The impact of patient characteristics on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The role of genetic factors in the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The influence of previous treatments on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The effect of dosage and administration frequency on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The correlation between the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The impact of side effects and adverse reactions on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The role of supportive care in improving the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

The effect of concurrent health conditions on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from CARTITUDE-4 was 11.8 months with a 95% Confidence Interval (CI) of (0.18, 0.38) ^{[1](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)}

Median PFS for K Maintenance?

The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) ^{[1](https://www.haematologica.org/article/view/haematol.2021.278399)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for K Maintenance? ### Response: The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) ^{[1](https://www.haematologica.org/article/view/haematol.2021.278399)}

Comparison of the median PFS for K Maintenance with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) ^{[1](https://www.haematologica.org/article/view/haematol.2021.278399)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for K Maintenance with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) ^{[1](https://www.haematologica.org/article/view/haematol.2021.278399)}

The impact of patient characteristics on the median PFS for K Maintenance.

The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) ^{[1](https://www.haematologica.org/article/view/haematol.2021.278399)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for K Maintenance. ### Response: The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) ^{[1](https://www.haematologica.org/article/view/haematol.2021.278399)}

The role of genetic factors in the median PFS for K Maintenance.

The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) ^{[1](https://www.haematologica.org/article/view/haematol.2021.278399)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for K Maintenance. ### Response: The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) ^{[1](https://www.haematologica.org/article/view/haematol.2021.278399)}

The influence of previous treatments on the median PFS for K Maintenance.

The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) ^{[1](https://www.haematologica.org/article/view/haematol.2021.278399)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for K Maintenance. ### Response: The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) ^{[1](https://www.haematologica.org/article/view/haematol.2021.278399)}

The effect of dosage and administration frequency on the median PFS for K Maintenance.

The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) ^{[1](https://www.haematologica.org/article/view/haematol.2021.278399)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for K Maintenance. ### Response: The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) ^{[1](https://www.haematologica.org/article/view/haematol.2021.278399)}

The correlation between the median PFS for K Maintenance and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) ^{[1](https://www.haematologica.org/article/view/haematol.2021.278399)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for K Maintenance and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) ^{[1](https://www.haematologica.org/article/view/haematol.2021.278399)}